先天性肾上腺皮质增生症 中国就医指南

Congenital Adrenal Hyperplasia (CAH) is a group of inherited autosomal recessive disorders characterized by enzymatic defects in the steroidogenesis pathway within the adrenal cortex. The most common form—accounting for over 90% of cases—is 21-hydroxylase deficiency, caused by mutations in the CYP21A2 gene. This defect impairs cortisol and often aldosterone synthesis, leading to compensatory adrenocorticotropic hormone (ACTH) overproduction, adrenal hyperplasia, and excessive accumulation of precursor steroids—particularly androgens. As a result, affected individuals may present with prenatal virilization in females (e.g., ambiguous genitalia), postnatal rapid growth and premature epiphyseal fusion, hypertension or salt-wasting crises (in severe classic forms), hirsutism, acne, menstrual irregularities, and infertility. Nonclassic CAH, a milder variant, often manifests later in childhood or adulthood with symptoms resembling polycystic ovary syndrome (PCOS) or idiopathic hirsutism. Epidemiologically, classic CAH occurs in approximately 1 in 10,000–15,000 live births globally, with higher prevalence in certain populations (e.g., 1 in 280 in the Yupik Eskimo population). Carrier frequency is estimated at 1 in 50–100 in most ethnic groups. Risk factors include consanguinity and family history; newborn screening programs—now implemented in all U.S. states and many high-income countries—enable early diagnosis and life-saving intervention. Without timely and lifelong management, CAH significantly impacts quality of life: children face psychosocial challenges related to genital surgery, short stature, and early puberty; adults report higher rates of anxiety, depression, sexual dysfunction, and reduced fertility. Chronic glucocorticoid replacement carries risks of obesity, insulin resistance, osteoporosis, and cardiovascular morbidity—underscoring the need for individualized dosing and multidisciplinary care involving endocrinologists, genetic counselors, pediatric urologists (when indicated), and mental health professionals. Lifelong adherence to medication, regular monitoring of hormone levels (17-OHP, androstenedione, renin), growth velocity, bone age, and metabolic parameters is essential to optimize outcomes and minimize complications.

# 先天性肾上腺皮质增生症（CAH）治疗方案与费用明细（内分泌科）

一、非手术/药物保守治疗（一线方案）

适用于经典型（21-羟化酶缺乏为主）、非经典型及所有稳定期患者。

• •基础激素替代：氢化可的松片（国产）0.5–1.5 mg/kg/d，年药费约 ¥1,200–¥3,600；地塞米松（需谨慎用于生育期女性）年费 ¥600–¥1,800
• •盐皮质激素补充：氟氢可的松片（0.05–0.2 mg/d），年费 ¥400–¥1,200
• •必需检查：血清17-OHP、雄烯二酮、皮质醇、电解质、骨龄X线（儿童）、肾上腺超声，单次检查费 ¥850–¥1,600；年度随访监测（含ACTH、睾酮/雌二醇、DHEA-S等） ¥2,200–¥3,800/年

二、手术干预方案（限特定并发症）

仅适用于严重外生殖器畸形（如女性假两性畸形）需整形矫正者，由内分泌科联合泌尿外科/妇科实施。

• •阴蒂成形术+阴道成形术（分期或一期）：术前评估（激素水平、影像学、心理评估） ¥2,500–¥4,200；手术+麻醉+住院（7–12天） ¥28,000–¥45,000（三甲医院标准）

三、特殊/复杂情况处理

• •糖皮质激素抵抗型CAH：加用阿比特龙（超说明书用药，需伦理审批），月均药费 ¥12,000–¥18,000
• •肾上腺危象抢救：静脉氢化可的松冲击+补液纠酸，单次急诊救治 ¥4,500–¥9,000
• •青春期延迟/不育管理：促性腺激素治疗或辅助生殖评估，年综合费用 ¥15,000–¥30,000

方案快速选择指南

✅ 婴幼儿/儿童初诊：首选氢化可的松+氟氢可的松，预算 ¥4,000–¥6,000/年 ✅ 成人非经典型：低剂量地塞米松+定期监测，预算 ¥3,000–¥5,000/年 ⚠️ 外生殖器显著畸形：转诊多学科会诊，预留手术总预算 ≥¥30,000 ❗ 危象或耐药：立即急诊入院，准备 ¥5,000–¥10,000 应急资金